RE:RE:RE:RE:RE:RE:RE:RE:VolumeThat's my point. Nothing they say will really change it much --only what they do can at this point. They've said all they can and to whomever is interested - instutituions and retail and it is where it is. Mostly, there aren't a lot of interested investors for all the rehased reasons.
You know I'm fully on board with them also upping the IR game, as you say, for all types of investors and see it as necessary. I support your critique and ideas. But with 3-4 months to go before hard data in humans, there's really not much else they can do that will have much of an effect. It's not worth going through the litany of pros/cons on the situation except to say not much seems to change it these days. Hence, only really good trial data will gain them an audience that will value the situation. If solid, the audience they and you hoped to see over the last year will build quicker than we imagine. Not much else will, unfortunately.
scarlet1967 wrote: The market doesn't have rose coloured glasses it is company's job to sell their rosy prospects to the market. Looking at SP and volume so far they haven't succeeded. Those upcoming milestones should move the needle but that process should have started while ago based on past achievements/milestones. It seems to me they keep producing the goods and no reaction from the market so we are hoping the next milestones create some interest. The fact that they have so far ignored the fast growing retail investors despite not much luck with analysts/institutional investors is hard to understand.Yes please keep executing but also make sure you get some credit for it. This is the ongoing issue which I am struggling with every darn day. We are in one of the longest and biggest bull markets ever preclinical companies are valued billions yet despite creating a phase whatever NASH protocol from thin air and a promising oncology phase1 or maybe we should call it preclinical since no human data thus far two legacy drugs with revenues THTX is constantly ascribed a discounted value compared to both oncology and NASH companies.They need to put it right and they need to do it yesterday.
Wino115 wrote: That's why this upcoming human data, basket trial and start of P2 is super important. It's the first time one can finally nail down their probabilities around a new drug and new large market. I also look forward to the day we see analysts tripping over each other to upgrade and we are in solid "stupidly overvalued" territory! I mean, huge revenue estimate, takeover spec, stupidly overvalued territory. Those 100 or so of us that read these posts deserve that and I hope the remainder of 2021 and 2022 brings it. It's ain't fast-tracked not to be running flat out fast and I expect it in 2022. The focus in your rose-colored glasses will be a lot clearer for us....
stockman75 wrote: Bucknelly21 wrote: SPCEO1 wrote: Those are the negatives, for sure. But there are also plenty of positives too. Glad you are OK! :)
Bucknelly21 wrote: I'm ok lol, just really bummed out how these guys have handled everything. They managed to isolate themselves from a massive bull market through bad market analysis for trogarzo, poor communication with the market, a bad strategy for reaching retail, burning analysts, offerings on bad terms ect. Maybe I just solved why it's the way it is lol
barely lol
Personally I will be happy when I no longer need to put on my rose colored glasses to find all the positives and try to read the tea leaves for how much incredible potential the company has and see that the next big thing is just right around the corner. It will be nice when I can take off the rose colored glasses and I can clearly see things reflected in the company and the stock price! Unfortunately the rest of the market doesn't have the high powered glasses that we have! The company has done a lousy job of convincing them to even pick up the darn glasses.